



SciTech Development, LLC

FOR IMMEDIATE RELEASE

SciTech Attending BIO 2019 at Philadelphia

(GROSSE POINTE FARMS, MI) May 8, 2019 – SciTech Development will be attending BIO 2019 on June 2-6 at Philadelphia, PA and is actively participating in the BIO One-on-One Partnering™ program. Visit the BIO online partnering portal (<https://convention.bio.org/partner/>) to set up investment and partnering meetings with SciTech. You can also call Earle Holsapple (Tel: 313-938-5517) or Don Zinn (Tel: 269-569-2794) directly before or during the event to schedule meetings or chat. Briefly, SciTech's lead oncology drug product ST-001 is an IND ready, immuno-oncology (IO), orphan designated drug with an FDA roadmap to an NDA post Phase 1b for multiple cancer indications.



About SciTech Development

SciTech Development, LLC is a clinical stage, biopharmaceutical company that has developed unique nano-delivery systems (SciTech Delivery Vehicle-SDV) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug is fenretinide which has been shown in extensive clinical trials to be a safe and effective anticancer therapy with targeted cancer destroying activity. The combination of the new SDV and fenretinide has led to SciTech's first drug product, ST-001, which holds the promise of improving and saving many lives. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. More information regarding SciTech's nano-delivery technology and oncology drug product ST-001 is available at <https://www.scitechdevelopment.com/>

For More Information: Earle T. Holsapple, President
SciTech Development, LLC
(313) 938-5517



###